Search

Your search keyword '"Faenzi, Elisa"' showing total 14 results
Start Over Author "Faenzi, Elisa"
14 results on '"Faenzi, Elisa"'

1. Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response

Author

Siena, Emilio, primary, Schiavetti, Francesca, additional, Borgogni, Erica, additional, Taccone, Marianna, additional, Faenzi, Elisa, additional, Brazzoli, Michela, additional, Aprea, Susanna, additional, Bardelli, Monia, additional, Volpini, Gianfranco, additional, Buricchi, Francesca, additional, Sammicheli, Chiara, additional, Tavarini, Simona, additional, Bechtold, Viviane, additional, Blohmke, Christoph J., additional, Cardamone, Dario, additional, De Intinis, Carlo, additional, Gonzalez-Lopez, Antonio, additional, O'Hagan, Derek T., additional, Nuti, Sandra, additional, Seidl, Claudia, additional, Didierlaurent, Arnaud M, additional, Bertholet, Sylvie, additional, D'Oro, Ugo, additional, Medini, Duccio, additional, and Finco, Oretta, additional

Published
2023
Full Text
View/download PDF

2. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies

Author

Faenzi, Elisa, Zedda, Luisanna, Bardelli, Monia, Spensieri, Fabiana, Borgogni, Erica, Volpini, Gianfranco, Buricchi, Francesca, Pasini, Franco Laghi, Capecchi, Pier Leopoldo, Montanaro, Fabio, Belli, Riccardo, Lattanzi, Maria, Piccirella, Simona, Montomoli, Emanuele, Ahmed, Syed Sohail, Rappuoli, Rino, Del Giudice, Giuseppe, Finco, Oretta, Castellino, Flora, and Galli, Grazia

Published
2012
Full Text
View/download PDF

3. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines

Author

Finco, Oretta, Frigimelica, Elisabetta, Buricchi, Francesca, Petracca, Roberto, Galli, Giuliano, Faenzi, Elisa, Meoni, Eva, Bonci, Alessandra, Agnusdei, Mauro, Nardelli, Filomena, Bartolini, Erika, Scarselli, Maria, Caproni, Elena, Laera, Donatello, Zedda, Luisanna, Skibinski, David, Giovinazzi, Serena, Bastone, Riccardo, Ianni, Elvira, Cevenini, Roberto, Grandi, Guido, and Grifantini, Renata

Published
2011

4. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults

Author

Leroux-Roels, Geert, primary, Lattanzi, Maria, additional, Solis, Claudia Dovali, additional, Contorni, Mario, additional, Costantini, Marco, additional, Moraschini, Luca, additional, Bardelli, Monia, additional, Bertholet, Sylvie, additional, Borgogni, Erica, additional, Buricchi, Francesca, additional, Cantisani, Rocco, additional, Faenzi, Elisa, additional, Finco, Oretta, additional, Leuzzi, Rosanna, additional, Pizza, Mariagrazia, additional, Rosa, Domenico, additional, Schiavetti, Francesca, additional, Seubert, Anja, additional, Spensieri, Fabiana, additional, Volpini, Gianfranco, additional, Zedda, Luisanna, additional, Giudice, Giuseppe Del, additional, and Galgani, Ilaria, additional

Published
2017
Full Text
View/download PDF

5. Analysis of the memory B cell response against glycoconjugate vaccines

Author

Faenzi, Elisa

Subjects
BIO/11 Biologia molecolare
Abstract

The development of vaccines directed against polysaccharide capsules of S. pneumoniae, H. influenzae and N. meningitidis have been of great importance in preventing potentially fatal infections. Bacterial capsular polysaccharides are T-cell-independent antigens that induce specific antibody response characterized by IgM immunoglobulins, with a very low IgG class switched response and lack of capability of inducing a booster response. The inability of pure polysaccharides to induce sustained immune responses has required the development of vaccines containing polysaccharides conjugated to a carrier protein, with the aim to generate T cell help. It is clear that the immunogenicity of glycoconjugate vaccines can vary depending on different factors, e.g. chemical nature of the linked polysaccharide, carrier protein, age of the target population, adjuvant used. The present study analyzes the memory B cell (MBC) response to the polysaccharide and to the carrier protein following vaccination with a glycoconjugate vaccine for the prevention of Group B streptococcus (GBS) infection. Not much is known about the role of adjuvants in the development of immunological memory raised against GBS polysaccharides, as well as about the influence of having a pre-existing immunity against the carrier protein on the B cell response raised against the polysaccharide component of the vaccine. We demonstrate in the mouse model that adjuvants can increase the antibody and memory B cell response to the carrier protein and to the conjugated polysaccharide. We also demonstrate that a pre-existing immunity to the carrier protein favors the development of the antibody and memory B cell response to subsequent vaccinations with a glycoconjugate, even in absence of adjuvants. These data provide a useful insight for a better understanding of the mechanism of action of this class of vaccines and for designing the best vaccine that could result in a productive and long lasting memory response.

Published
2012
Full Text
View/download PDF

6. Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes

Author

Viciani, Elisa, primary, Montagnani, Francesca, additional, Tavarini, Simona, additional, Tordini, Giacinta, additional, Maccari, Silvia, additional, Morandi, Matteo, additional, Faenzi, Elisa, additional, Biagini, Cesare, additional, Romano, Antonio, additional, Salerni, Lorenzo, additional, Finco, Oretta, additional, Lazzi, Stefano, additional, Ruggiero, Paolo, additional, De Luca, Andrea, additional, Barocchi, Michèle A., additional, and Manetti, Andrea G. O., additional

Published
2016
Full Text
View/download PDF

7. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.

Author

Leroux-Roels, Geert, Lattanzi, Maria, Solis, Claudia Dovali, Contorni, Mario, Costantini, Marco, Moraschini, Luca, Bardelli, Monia, Bertholet, Sylvie, Borgogni, Erica, Buricchi, Francesca, Cantisani, Rocco, Faenzi, Elisa, Finco, Oretta, Leuzzi, Rosanna, Pizza, Mariagrazia, Rosa, Domenico, Schiavetti, Francesca, Seubert, Anja, Spensieri, Fabiana, and Volpini, Gianfranco

Published
2018
Full Text
View/download PDF

8. Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivo

Author

Massachusetts Institute of Technology. Department of Biology, Whitehead Institute for Biomedical Research, Ploegh, Hidde, Popp, Maximilian W.L., Nair, Nitya, Buti, Ludovico, Faenzi, Elisa, Buricchi, Francesca, Nuti, Sandra, Sammicheli, Chiara, Tavarini, Simona, Berti, Francesco, Pizza, Mariagrazia, Castellino, Flora, Finco, Oretta, Rappuoli, Rino, Del Giudice, Giuseppe, Galli, Grazia, Bardelli, Monia, Massachusetts Institute of Technology. Department of Biology, Whitehead Institute for Biomedical Research, Ploegh, Hidde, Popp, Maximilian W.L., Nair, Nitya, Buti, Ludovico, Faenzi, Elisa, Buricchi, Francesca, Nuti, Sandra, Sammicheli, Chiara, Tavarini, Simona, Berti, Francesco, Pizza, Mariagrazia, Castellino, Flora, Finco, Oretta, Rappuoli, Rino, Del Giudice, Giuseppe, Galli, Grazia, and Bardelli, Monia

Abstract

Antigen-specific memory B cells generate anamnestic responses and high affinity antibodies upon re-exposure to pathogens. Attempts to isolate rare antigen-specific memory B cells for in-depth functional analysis at the single-cell level have been hindered by the lack of tools with adequate sensitivity. We applied two independent methods of protein labeling to sensitive and specific ex vivo identification of antigen-specific memory B cells by flow cytometry: stringently controlled amine labeling, and sortagging, a novel method whereby a single nucleophilic fluorochrome molecule is added onto an LPETG motif carried by the target protein. We show that sortagged NadA, a major antigen in the meningococcal serogroup B vaccine, identifies NadA-specific memory B cells with high sensitivity and specificity, comparable to NadA amine-labeled under stringent reaction parameters in a mouse model of vaccination. We distinguish NadA-specific switched MBC induced by vaccination from the background signal contributed by splenic transitional and marginal zone B cells. In conclusion, we demonstrate that protein structural data coupled with sortag technology allows the development of engineered antigens that are as sensitive and specific as conventional chemically labeled antigens in detecting rare MBC, and minimize the possibility of disrupting conformational B cell epitopes.

Published
2014

9. Analysis of the memory B cell response against glycoconjugate vaccines

Author

Scarlato, Vincenzo, Faenzi, Elisa <1981>, Scarlato, Vincenzo, and Faenzi, Elisa <1981>

Abstract

The development of vaccines directed against polysaccharide capsules of S. pneumoniae, H. influenzae and N. meningitidis have been of great importance in preventing potentially fatal infections. Bacterial capsular polysaccharides are T-cell-independent antigens that induce specific antibody response characterized by IgM immunoglobulins, with a very low IgG class switched response and lack of capability of inducing a booster response. The inability of pure polysaccharides to induce sustained immune responses has required the development of vaccines containing polysaccharides conjugated to a carrier protein, with the aim to generate T cell help. It is clear that the immunogenicity of glycoconjugate vaccines can vary depending on different factors, e.g. chemical nature of the linked polysaccharide, carrier protein, age of the target population, adjuvant used. The present study analyzes the memory B cell (MBC) response to the polysaccharide and to the carrier protein following vaccination with a glycoconjugate vaccine for the prevention of Group B streptococcus (GBS) infection. Not much is known about the role of adjuvants in the development of immunological memory raised against GBS polysaccharides, as well as about the influence of having a pre-existing immunity against the carrier protein on the B cell response raised against the polysaccharide component of the vaccine. We demonstrate in the mouse model that adjuvants can increase the antibody and memory B cell response to the carrier protein and to the conjugated polysaccharide. We also demonstrate that a pre-existing immunity to the carrier protein favors the development of the antibody and memory B cell response to subsequent vaccinations with a glycoconjugate, even in absence of adjuvants. These data provide a useful insight for a better understanding of the mechanism of action of this class of vaccines and for designing the best vaccine that could result in a productive and long lasting memory response.

Published
2012

10. Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivo

Author

Nair, Nitya, primary, Buti, Ludovico, additional, Faenzi, Elisa, additional, Buricchi, Francesca, additional, Nuti, Sandra, additional, Sammicheli, Chiara, additional, Tavarini, Simona, additional, Popp, Maximilian W.L., additional, Ploegh, Hidde, additional, Berti, Francesco, additional, Pizza, Mariagrazia, additional, Castellino, Flora, additional, Finco, Oretta, additional, Rappuoli, Rino, additional, Del Giudice, Giuseppe, additional, Galli, Grazia, additional, and Bardelli, Monia, additional

Published
2013
Full Text
View/download PDF

11. CT043, a Protective Antigen That Induces a CD4 + Th1 Response during Chlamydia trachomatis Infection in Mice and Humans

Author

Meoni, Eva, primary, Faenzi, Elisa, additional, Frigimelica, Elisabetta, additional, Zedda, Luisanna, additional, Skibinski, David, additional, Giovinazzi, Serena, additional, Bonci, Alessandra, additional, Petracca, Roberto, additional, Bartolini, Erika, additional, Galli, Giuliano, additional, Agnusdei, Mauro, additional, Nardelli, Filomena, additional, Buricchi, Francesca, additional, Norais, Nathalie, additional, Ferlenghi, Ilaria, additional, Donati, Manuela, additional, Cevenini, Roberto, additional, Finco, Oretta, additional, Grandi, Guido, additional, and Grifantini, Renata, additional

Published
2009
Full Text
View/download PDF

12. CT043, a Protective Antigen That Induces a CD4+Th1 Response during Chlamydia trachomatisInfection in Mice and Humans

Author

Meoni, Eva, Faenzi, Elisa, Frigimelica, Elisabetta, Zedda, Luisanna, Skibinski, David, Giovinazzi, Serena, Bonci, Alessandra, Petracca, Roberto, Bartolini, Erika, Galli, Giuliano, Agnusdei, Mauro, Nardelli, Filomena, Buricchi, Francesca, Norais, Nathalie, Ferlenghi, Ilaria, Donati, Manuela, Cevenini, Roberto, Finco, Oretta, Grandi, Guido, and Grifantini, Renata

Abstract

ABSTRACTDespite several decades of intensive studies, no vaccines against Chlamydia trachomatis, an intracellular pathogen causing serious ocular and urogenital diseases, are available yet. Infection-induced immunity in both animal models and humans strongly supports the notion that for a vaccine to be effective a strong CD4+Th1 immune response should be induced. In the course of our vaccine screening program based on the selection of chlamydial proteins eliciting cell-mediated immunity, we have found that CT043, a protein annotated as hypothetical, induces CD4+Th1 cells both in chlamydia-infected mice and in human patients with diagnosed C. trachomatisgenital infection. DNA priming/protein boost immunization with CT043 results in a 2.6-log inclusion-forming unit reduction in the murine lung infection model. Sequence analysis of CT043 from C. trachomatishuman isolates belonging to the most representative genital serovars revealed a high degree of conservation, suggesting that this antigen could provide cross-serotype protection. Therefore, CT043 is a promising vaccine candidate against C. trachomatisinfection.

Published
2009
Full Text
View/download PDF

13. CT043, a Protective Antigen That Induces a CD4+Th1 Response during Chlamydia trachomatis Infection in Mice and Humans

Author

Meoni, Eva, Faenzi, Elisa, Frigimelica, Elisabetta, Zedda, Luisanna, Skibinski, David, Giovinazzi, Serena, Bonci, Alessandra, Petracca, Roberto, Bartolini, Erika, Galli, Giuliano, Agnusdei, Mauro, Nardelli, Filomena, Buricchi, Francesca, Norais, Nathalie, Ferlenghi, Ilaria, Donati, Manuela, Cevenini, Roberto, Finco, Oretta, Grandi, Guido, and Grifantini, Renata

Abstract

Despite several decades of intensive studies, no vaccines against Chlamydia trachomatis, an intracellular pathogen causing serious ocular and urogenital diseases, are available yet. Infection-induced immunity in both animal models and humans strongly supports the notion that for a vaccine to be effective a strong CD4+Th1 immune response should be induced. In the course of our vaccine screening program based on the selection of chlamydial proteins eliciting cell-mediated immunity, we have found that CT043, a protein annotated as hypothetical, induces CD4+Th1 cells both in chlamydia-infected mice and in human patients with diagnosed C. trachomatis genital infection. DNA priming/protein boost immunization with CT043 results in a 2.6-log inclusion-forming unit reduction in the murine lung infection model. Sequence analysis of CT043 from C. trachomatis human isolates belonging to the most representative genital serovars revealed a high degree of conservation, suggesting that this antigen could provide cross-serotype protection. Therefore, CT043 is a promising vaccine candidate against C. trachomatis infection.

Published
2009

14. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans.

Author

Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S, Bonci A, Petracca R, Bartolini E, Galli G, Agnusdei M, Nardelli F, Buricchi F, Norais N, Ferlenghi I, Donati M, Cevenini R, Finco O, Grandi G, and Grifantini R

Subjects
Animals, Bacterial Vaccines immunology, Chlamydia muridarum immunology, Female, Genital Diseases, Female immunology, Humans, Immunization, Interferon-gamma biosynthesis, Mice, Mice, Inbred BALB C, Porins immunology, Antigens, Bacterial immunology, Chlamydia Infections immunology, Chlamydia trachomatis immunology, Th1 Cells immunology
Abstract

Despite several decades of intensive studies, no vaccines against Chlamydia trachomatis, an intracellular pathogen causing serious ocular and urogenital diseases, are available yet. Infection-induced immunity in both animal models and humans strongly supports the notion that for a vaccine to be effective a strong CD4(+) Th1 immune response should be induced. In the course of our vaccine screening program based on the selection of chlamydial proteins eliciting cell-mediated immunity, we have found that CT043, a protein annotated as hypothetical, induces CD4(+) Th1 cells both in chlamydia-infected mice and in human patients with diagnosed C. trachomatis genital infection. DNA priming/protein boost immunization with CT043 results in a 2.6-log inclusion-forming unit reduction in the murine lung infection model. Sequence analysis of CT043 from C. trachomatis human isolates belonging to the most representative genital serovars revealed a high degree of conservation, suggesting that this antigen could provide cross-serotype protection. Therefore, CT043 is a promising vaccine candidate against C. trachomatis infection.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results